Hims & Hers introduced a $49 per month compounded semaglutide pill in early February— then pulled it from the market two days ...
Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a ...
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new ...
‘It’s not an easy pill to take’: The first highly anticipated GLP-1 pill is here, but physicians aren’t sure it has the ...
When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...
Novo Nordisk A/S’ television ad introducing the tablet form of its weight-loss drug, Wegovy (semaglutide), to American consumers didn’t pass regulatory muster.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results